Literature DB >> 21286724

The role of randomized controlled trials in evidence-based urology.

Luke T Lavallée1, Dean Fergusson, Rodney H Breau.   

Abstract

PURPOSE: To review the current and future role of randomized controlled trials (RCTs) in urology.
METHODS: A review of the urological literature was performed to assess the current role of RCTs in urology. These findings were put in context of current practice, and methodologic limitations of observational study design were discussed.
RESULTS: Several RCTs have improved treatment of urology patients. However, overall, few studies in the urologic literature convey high-level evidence. RCTs represent the only study design that can assess causality, thus are the only means to significantly advance knowledge about therapy and improve patient care. Increased incidence and improved quality of RCTs may be achieved through education, community outreach, and better access to research infrastructure.
CONCLUSIONS: RCTs have significantly improved urologic practice. RCTs are superior to observational studies because of decreased risk of bias and confounding. To further advance clinical practice, clinical trials must play a predominant role and should be embraced by the urology community.

Entities:  

Mesh:

Year:  2011        PMID: 21286724     DOI: 10.1007/s00345-011-0646-7

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  29 in total

1.  Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group.

Authors:  H C Bucher; G H Guyatt; D J Cook; A Holbrook; F A McAlister
Journal:  JAMA       Date:  1999-08-25       Impact factor: 56.272

2.  Serum selenium and subsequent risk of prostate cancer.

Authors:  A M Nomura; J Lee; G N Stemmermann; G F Combs
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-09       Impact factor: 4.254

3.  Evidence-based medicine training in residency: a survey of urology programme directors.

Authors:  Philipp Dahm; Glenn M Preminger; Charles D Scales; Susan F Fesperman; Lawrence L Yeung; Marc S Cohen
Journal:  BJU Int       Date:  2009-02       Impact factor: 5.588

4.  Effect of dutasteride on the risk of prostate cancer.

Authors:  Gerald L Andriole; David G Bostwick; Otis W Brawley; Leonard G Gomella; Michael Marberger; Francesco Montorsi; Curtis A Pettaway; Teuvo L Tammela; Claudio Teloken; Donald J Tindall; Matthew C Somerville; Timothy H Wilson; Ivy L Fowler; Roger S Rittmaster
Journal:  N Engl J Med       Date:  2010-04-01       Impact factor: 91.245

5.  A retrospective quality analysis of 102 randomized trials in four leading urological journals from 1984-1989.

Authors:  V Lent; A Langenbach
Journal:  Urol Res       Date:  1996

6.  Blinding in randomised trials: hiding who got what.

Authors:  Kenneth F Schulz; David A Grimes
Journal:  Lancet       Date:  2002-02-23       Impact factor: 79.321

7.  Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer.

Authors:  K Yoshizawa; W C Willett; S J Morris; M J Stampfer; D Spiegelman; E B Rimm; E Giovannucci
Journal:  J Natl Cancer Inst       Date:  1998-08-19       Impact factor: 13.506

8.  Efficacy of tamsulosin in the medical management of juxtavesical ureteral stones.

Authors:  Marco Dellabella; Giulio Milanese; Giovanni Muzzonigro
Journal:  J Urol       Date:  2003-12       Impact factor: 7.450

9.  Statin use and risk of prostate cancer in the California Men's Health Study cohort.

Authors:  E Dawn Flick; Laurel A Habel; K Arnold Chan; Stephen K Van Den Eeden; Virginia P Quinn; Reina Haque; Endel J Orav; John D Seeger; Marianne C Sadler; Charles P Quesenberry; Barbara Sternfeld; Steven J Jacobsen; Rachel A Whitmer; Bette J Caan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-10-30       Impact factor: 4.254

10.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

View more
  2 in total

1.  Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study.

Authors:  Daniel A Barocas; Vivien Chen; Matthew Cooperberg; Michael Goodman; John J Graff; Sheldon Greenfield; Ann Hamilton; Karen Hoffman; Sherrie Kaplan; Tatsuki Koyama; Alicia Morgans; Lisa E Paddock; Sharon Phillips; Matthew J Resnick; Antoinette Stroup; Xiao-Cheng Wu; David F Penson
Journal:  J Comp Eff Res       Date:  2013-07       Impact factor: 1.744

2.  Establishment of the Seoul National University Prospectively Enrolled Registry for Genitourinary Cancer (SUPER-GUC): A prospective, multidisciplinary, bio-bank linked cohort and research platform.

Authors:  Chang Wook Jeong; Jungyo Suh; Hyeong Dong Yuk; Bum Sik Tae; Miso Kim; Bhumsuk Keam; Jin Ho Kim; Sang Youn Kim; Jeong Yeon Cho; Seung Hyup Kim; Kyung Chul Moon; Gi Jeong Cheon; Ja Hyeon Ku; Hyeon Hoe Kim; Cheol Kwak
Journal:  Investig Clin Urol       Date:  2019-05-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.